LGND
Ligand Pharmaceuticals (LGND) P/E Ratio
P/E Ratio as of Oct 30, 2026: 143.96
Average51.39
Median32.45
Minimum31.35
Maximum143.96
143.96
110.78 (333.88%)past month
The P/E ratio for Ligand Pharmaceuticals (LGND) is 143.96 as of Oct 30, 2026. This represents a increase of 233.86% compared to its 12-month average P/E ratio of 43.12. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Ligand Pharmaceuticals P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Ligand Pharmaceuticals’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Ligand Pharmaceuticals to industry peers.
Ligand Pharmaceuticals P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Ligand Pharmaceuticals’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Ligand Pharmaceuticals to industry peers.
Ligand Pharmaceuticals (LGND) P/E Ratio Insights
See Ligand Pharmaceuticals’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Ligand Pharmaceuticals (LGND)
Order type
Buy in
Order amount
Est. shares
0 shares
Ligand Pharmaceuticals (LGND) P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Oct 1, 2026 | $302.74 | 32.37 |
| Sep 1, 2026 | $284.27 | 30.39 |
| Aug 3, 2026 | $292.04 | 39.60 |
| Jul 1, 2026 | $312.01 | 42.30 |
| Jun 1, 2026 | $229.78 | 31.15 |
| May 1, 2026 | $227.44 | 38.98 |
| Apr 1, 2026 | $199.62 | 34.21 |
| Mar 2, 2026 | $202.55 | 34.71 |
| Feb 2, 2026 | $197.93 | 95.27 |
| Jan 2, 2026 | $190.11 | 91.50 |
Ligand Pharmaceuticals (LGND) End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2026 | 143.96 | +58.20% |
| 2025 | 91.00 | +113.46% |
| 2024 | 42.63 | -50.06% |
| 2023 | 85.36 | -258.54% |
| 2022 | -53.84 | -291.06% |
| 2021 | 28.18 | — |
FAQs About Ligand Pharmaceuticals (LGND) P/E ratio
The latest P/E ratio of Ligand Pharmaceuticals (LGND) is 143.96, as of Oct 30, 2026. This is calculated based on its current stock price and earnings per share (EPS).
Ligand Pharmaceuticals’s last 12-month average P/E ratio is 43.12, compared to its current P/E ratio of 143.96. This reflects a increase of 233.86%.
Ligand Pharmaceuticals’s current P/E ratio of 143.96 is higher than its last 12-month average P/E of 43.12. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Ligand Pharmaceuticals’s average P/E ratio over the last 3 years is -31.25. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Ligand Pharmaceuticals’s average P/E ratio over the last 5 years is -18.34. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.
Ligand Pharmaceuticals (LGND) P/E Ratio Insights
See Ligand Pharmaceuticals’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Ligand Pharmaceuticals (LGND)
Order type
Buy in
Order amount
Est. shares
0 shares
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.